Table 5.
ASAS40 and BASDAI 50 response rates at week 12 in patients with AS stratified by prior anti-TNF therapy
| ASAS40 | BASDAI 50 | |||||
|---|---|---|---|---|---|---|
| Response rate, n/N (%) | Unadjusted odds ratio | P value | Response rate, n/N (%) | Unadjusted odds ratio | P value | |
| (95% CI) | (95% CI) | |||||
| History of prior anti-TNF therapy | ||||||
| Prior ETN or IFX or both | 115/305 (37.7) | 0.41 (0.32 to 0.54) | < 0.001 | 128/314 (40.8) | 0.40 (0.31 to 0.53) | < 0.001 |
| No prior ETN/IFXa | 518/873 (59.3) | 561/890 (63.0) | ||||
| Prior TNF antagonist(s) | ||||||
| ETN only | 25/81 (30.9) | 0.93 (0.47 to 1.83) | 0.083 | 27/81 (33.3) | 0.98 (0.51 to 1.90) | 0.033 |
| IFX only | 66/150 (44.0) | 1.64 (0.91 to 2.93) | 75/156 (48.1) | 1.82 (1.03 to 3.20) | ||
| ETN and IFXa | 24/74 (32.4) | 26/77 (33.8) | ||||
| Reason for discontinuation of prior TNF antagonist | ||||||
| Loss of response | 46/108 (42.6) | 2.09 (1.05 to 4.14) | 0.108 | 47/112 (42.0) | 2.03 (1.03 to 4.03) | 0.059 |
| Intolerance | 20/52 (38.5) | 1.76 (0.79 to 3.91) | 25/54 (46.3) | 2.42 (1.11 to 5.30) | ||
| Lack of responsea | 16/61 (26.2) | 16/61 (26.2) | ||||
aUsed as reference value. AS, ankylosing spondylitis; ASAS40, Assessment of SpondyloArthritis international Society 40% response; BASDAI 50, Bath AS Disease Activity Index 50% response; CI, confidence interval; ETA, etanercept; IFX, infliximab; TNF, tumor necrosis factor.